<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02161016</url>
  </required_header>
  <id_info>
    <org_study_id>map3-2014</org_study_id>
    <nct_id>NCT02161016</nct_id>
  </id_info>
  <brief_title>A Clinical Study of Outcomes in Foot and Ankle Bone Grafting Using map3® Cellular Allogeneic Bone Graft</brief_title>
  <official_title>A Radiographic and Clinical Outcomes Study Evaluating map3® Cellular Allogeneic Bone Graft in Patients Undergoing Bone Grafting in the Foot/Ankle</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RTI Surgical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RTI Surgical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single arm pilot study in patients requiring surgical fusion in the foot or ankle.&#xD;
      Patients will receive map3® Cellular Allogeneic Bone Graft containing donor matched stem&#xD;
      cells. This cohort study will enroll 24 patients total at 1 site. After subjects have signed&#xD;
      an informed consent, the baseline visit and examinations will be completed. Patients will be&#xD;
      evaluated at 2 weeks, 6 weeks, 3 months, 6 months, 12 months, and 24 months after surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      map3® Cellular Allogeneic Bone Graft provides the desired osteoconductive, osteoinductive and&#xD;
      osteogenic potential capacities which are essential to optimal fracture healing when bone&#xD;
      grafts are implanted. It offers viable MAPC-class cells on a scaffold comprised of&#xD;
      demineralize bone matrix (DBM) and cortical cancellous chips. map3® Cellular Allogeneic Bone&#xD;
      Graft is considered an allograft, and as such, is indicated for bone repair for orthopaedic&#xD;
      indications where autograft is employed. The primary goal of this study is to evaluate the&#xD;
      outcomes in bone grafts of the foot or ankle using a stem cell modified allograft (map3®&#xD;
      Cellular Allogeneic Bone Graft). The study endpoints will be objectively determined via&#xD;
      x-rays and CT scan to assess bony fusion, extremity evaluation using the AFAS and subjective&#xD;
      patient scores for foot disabilities and quality of life.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    slow recruitment&#xD;
  </why_stopped>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AOFAS Foot-and-Ankle Score</measure>
    <time_frame>24 months</time_frame>
    <description>The American Orthopaedic Foot and Ankle Society score returns an indexed score, from 0 - 100, to assess clinical outcomes following foot /ankle surgery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>SF-36 Score</measure>
    <time_frame>24 months</time_frame>
    <description>The SF-36 is a survey for health and well-being.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Foot Ankle Disability Index</measure>
    <time_frame>24 months</time_frame>
    <description>The Foot Ankle Disability Index (FADI) is a self-report of function that assesses activities of daily living, with scores ranging from 0 to 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CT Scan</measure>
    <time_frame>6 months</time_frame>
    <description>A CT scan will be done at 6 months in order to assess bone fusion.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Time to Full Weight-bearing</measure>
    <time_frame>up to 24 months</time_frame>
    <description>This will be the time from the date of surgery until the patient has full, unassisted weight bearing, and will be measured in weeks.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Foot Deformities, Acquired</condition>
  <condition>Disorder of Joint of Foot</condition>
  <condition>Fracture of Foot</condition>
  <condition>Deformity of Bone</condition>
  <arm_group>
    <arm_group_label>map3 allogeneic bone graft</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients will receive map3® Cellular Allogeneic Bone Graft containing donor matched stem cells.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>map3</intervention_name>
    <description>Patients will receive map3® Cellular Allogeneic Bone Graft containing donor matched stem cells.</description>
    <arm_group_label>map3 allogeneic bone graft</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Study subjects will be limited to patients with foot/ankle pathologies requiring&#xD;
             fusion, which include midfoot, hindfoot, ankle, double and triple arthrodesis using&#xD;
             open surgical technique with supplemental bone graft substitute.&#xD;
&#xD;
          -  Life expectancy of at least twenty four (24) months&#xD;
&#xD;
          -  Ability to give written informed consent&#xD;
&#xD;
          -  All subjects will have a minimum age of eighteen (18) years and a maximum of eighty&#xD;
             (80) years.&#xD;
&#xD;
          -  Both male and non-pregnant female subjects will be included.&#xD;
&#xD;
          -  To facilitate follow-up, study subjects will be limited to the local geographic area&#xD;
             of the study site and must be willing to use the rehabilitation facility and physical&#xD;
             therapy schedule assigned by the surgeon.&#xD;
&#xD;
          -  All subjects must be able to read, write, and comprehend instructions and guidelines&#xD;
             in English and understand (and sign as an acknowledgment of their understanding) an&#xD;
             informed consent declaration&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who have been diagnosed with Charcot foot&#xD;
&#xD;
          -  Patients requiring osteotomies or undergoing a revision surgery for non-union&#xD;
&#xD;
          -  Patients with additional lower limb injuries requiring concomitant procedures not&#xD;
             related to the current foot/ankle procedure&#xD;
&#xD;
          -  Patients with soft tissue compromise involving open and/or infected wounds on the&#xD;
             study limb&#xD;
&#xD;
          -  Patients requiring any other bone grafting product other than study product (map3®&#xD;
             Cellular Allogeneic Bone Graft) e.g. rhBMP2 (recombinant human bone morphogenetic&#xD;
             protein 2).&#xD;
&#xD;
          -  Patients with confirmed diagnosis of abnormal lower limb vasculature or peripheral&#xD;
             vascular disease&#xD;
&#xD;
          -  Patients with a high Body Mass Index ( BMI &gt; 35)&#xD;
&#xD;
          -  Diagnosis of osteonecrosis, metabolic bone diseases or gout&#xD;
&#xD;
          -  Diabetic patients who are insulin dependent&#xD;
&#xD;
          -  Patients who have received any treatment within the past 12 months which may interfere&#xD;
             with bone metabolism (bisphosphonates and/or calcitonin).&#xD;
&#xD;
          -  Patients using glucocorticoids &gt; 10 mg/day&#xD;
&#xD;
          -  Chronic use (≥ 90 days) of non-steroidal anti-inflammatory drugs (NSAIDS)&#xD;
&#xD;
          -  Patients with active cancer or a history of any cancer&#xD;
&#xD;
          -  Known allergies to Dimethyl Sulfoxide (DMSO) and/or Human Serum Albumin (HSA)&#xD;
&#xD;
          -  Pregnant or lactating females or who are capable of reproduction and will not take&#xD;
             acceptable measures to prevent reproduction during the study&#xD;
&#xD;
          -  Patients who have tested positive for HTLV, HIV, hepatitis B or hepatitis C, have&#xD;
             rheumatoid arthritis, an autoimmune disease or are on chronic immunosuppressive&#xD;
             medications&#xD;
&#xD;
          -  Require chronic use (≥ 90 days) of anticoagulation therapy&#xD;
&#xD;
          -  Active smokers unwilling to comply with surgeons instructions to stop smoking seven&#xD;
             (7) days prior to surgery through three (3) month post-op visit&#xD;
&#xD;
          -  History of alcohol or drug abuse within 90 days of screening&#xD;
&#xD;
          -  Patients currently enrolled or have been enrolled in clinical studies evaluating&#xD;
             investigational devices, pharmaceuticals or biologics within 90 days of enrollment.&#xD;
&#xD;
          -  Patients unable to give written informed consent and any vulnerable patient population&#xD;
&#xD;
          -  Inability to comply with all requirements of this investigation, as well as follow the&#xD;
             instructions of the physician&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Craig Radnay, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Saint Francis Memorial Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Saint Francis Hospital</name>
      <address>
        <city>Roslyn</city>
        <state>New York</state>
        <zip>11576</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Guyton GP, Miller SD. Stem cells in bone grafting: Trinity allograft with stem cells and collagen/beta-tricalcium phosphate with concentrated bone marrow aspirate. Foot Ankle Clin. 2010 Dec;15(4):611-9. doi: 10.1016/j.fcl.2010.09.003. Review.</citation>
    <PMID>21056860</PMID>
  </reference>
  <reference>
    <citation>Clements JR. Use of allograft cellular bone matrix in multistage talectomy with tibiocalcaneal arthrodesis: a case report. J Foot Ankle Surg. 2012 Jan-Feb;51(1):83-6. doi: 10.1053/j.jfas.2011.09.002. Epub 2011 Oct 20.</citation>
    <PMID>22014833</PMID>
  </reference>
  <verification_date>February 2015</verification_date>
  <study_first_submitted>June 6, 2014</study_first_submitted>
  <study_first_submitted_qc>June 9, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2014</study_first_posted>
  <results_first_submitted>February 26, 2015</results_first_submitted>
  <results_first_submitted_qc>March 31, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 1, 2015</results_first_posted>
  <last_update_submitted>March 31, 2015</last_update_submitted>
  <last_update_submitted_qc>March 31, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 1, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Foot Deformities</mesh_term>
    <mesh_term>Foot Deformities, Congenital</mesh_term>
    <mesh_term>Joint Diseases</mesh_term>
    <mesh_term>Foot Deformities, Acquired</mesh_term>
    <mesh_term>Congenital Abnormalities</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>map3 Allogeneic Bone Graft</title>
          <description>Patients will receive map3® Cellular Allogeneic Bone Graft containing donor matched stem cells.&#xD;
map3: Patients will receive map3® Cellular Allogeneic Bone Graft containing donor matched stem cells.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>withdrawn by IRB</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>map3 Allogeneic Bone Graft</title>
          <description>Patients will receive map3® Cellular Allogeneic Bone Graft containing donor matched stem cells.&#xD;
map3: Patients will receive map3® Cellular Allogeneic Bone Graft containing donor matched stem cells.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>AOFAS Foot-and-Ankle Score</title>
        <description>The American Orthopaedic Foot and Ankle Society score returns an indexed score, from 0 - 100, to assess clinical outcomes following foot /ankle surgery.</description>
        <time_frame>24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>map3 Allogeneic Bone Graft</title>
            <description>Patients will receive map3® Cellular Allogeneic Bone Graft containing donor matched stem cells.&#xD;
map3: Patients will receive map3® Cellular Allogeneic Bone Graft containing donor matched stem cells.</description>
          </group>
        </group_list>
        <measure>
          <title>AOFAS Foot-and-Ankle Score</title>
          <description>The American Orthopaedic Foot and Ankle Society score returns an indexed score, from 0 - 100, to assess clinical outcomes following foot /ankle surgery.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SF-36 Score</title>
        <description>The SF-36 is a survey for health and well-being.</description>
        <time_frame>24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>map3 Allogeneic Bone Graft</title>
            <description>Patients will receive map3® Cellular Allogeneic Bone Graft containing donor matched stem cells.&#xD;
map3: Patients will receive map3® Cellular Allogeneic Bone Graft containing donor matched stem cells.</description>
          </group>
        </group_list>
        <measure>
          <title>SF-36 Score</title>
          <description>The SF-36 is a survey for health and well-being.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Foot Ankle Disability Index</title>
        <description>The Foot Ankle Disability Index (FADI) is a self-report of function that assesses activities of daily living, with scores ranging from 0 to 100.</description>
        <time_frame>24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>map3 Allogeneic Bone Graft</title>
            <description>Patients will receive map3® Cellular Allogeneic Bone Graft containing donor matched stem cells.&#xD;
map3: Patients will receive map3® Cellular Allogeneic Bone Graft containing donor matched stem cells.</description>
          </group>
        </group_list>
        <measure>
          <title>Foot Ankle Disability Index</title>
          <description>The Foot Ankle Disability Index (FADI) is a self-report of function that assesses activities of daily living, with scores ranging from 0 to 100.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CT Scan</title>
        <description>A CT scan will be done at 6 months in order to assess bone fusion.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>map3 Allogeneic Bone Graft</title>
            <description>Patients will receive map3® Cellular Allogeneic Bone Graft containing donor matched stem cells.&#xD;
map3: Patients will receive map3® Cellular Allogeneic Bone Graft containing donor matched stem cells.</description>
          </group>
        </group_list>
        <measure>
          <title>CT Scan</title>
          <description>A CT scan will be done at 6 months in order to assess bone fusion.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Time to Full Weight-bearing</title>
        <description>This will be the time from the date of surgery until the patient has full, unassisted weight bearing, and will be measured in weeks.</description>
        <time_frame>up to 24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>map3 Allogeneic Bone Graft</title>
            <description>Patients will receive map3® Cellular Allogeneic Bone Graft containing donor matched stem cells.&#xD;
map3: Patients will receive map3® Cellular Allogeneic Bone Graft containing donor matched stem cells.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Full Weight-bearing</title>
          <description>This will be the time from the date of surgery until the patient has full, unassisted weight bearing, and will be measured in weeks.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>map3 Allogeneic Bone Graft</title>
          <description>Patients will receive map3® Cellular Allogeneic Bone Graft containing donor matched stem cells.&#xD;
map3: Patients will receive map3® Cellular Allogeneic Bone Graft containing donor matched stem cells.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Robin Waite</name_or_title>
      <organization>RTI Surgical</organization>
      <phone>386-418-8888</phone>
      <email>rwaite@rtix.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

